Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study

Ziyan Tong; Ning Zhu; Hong Shen; Ying Yuan

doi:10.1002/cac2.12611

Cancer Communications ›› 2024, Vol. 44 ›› Issue (12) : 1381 -1384. DOI: 10.1002/cac2.12611

RESEARCH HIGHLIGHT

Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study

Ziyan Tong ¹^,²
, Ning Zhu ¹^,²
, Hong Shen ¹^,²^,^†
, Ying Yuan ¹^,²^,³^,⁴^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Ziyan Tong, Ning Zhu, Hong Shen, Ying Yuan. Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study. Cancer Communications, 2024, 44(12): 1381-1384 DOI:10.1002/cac2.12611

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Spigel DR, Faivre-Finn C. Gray JE, Vicente D, Planchard D, Paz-Ares L. et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12): 1301–1311.

[2]	Naidoo J, Antonia S, Wu YL, Cho BC, Thiyagarajah P, Mann H, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023; 18(5): 657–663.

[3]	Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024; 391(7): 585–597.

[4]	Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2): 113–125.

[5]	Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10): 1830-1840.

[6]	Akamatsu H, Murakami H, Harada H, Shimizu J, Hayashi H, Daga H, et al. Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. J Thorac Oncol. 2021; 16(10): 1745–1752.

[7]

Xing L, Wu G, Wang L, Li J, Wang J, Yuan Z, et al. Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2021; 109(5): 1349–1358.

[8]	Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, et al. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024; 19(6): 928–940.

[9]

John T, Grohe C, Goldman JW, Kato T, Laktionov KK, Bonanno L, et al. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2024; 42(16_suppl): 8005–8005.

[10]	Bi N, Xu K, Ge H, Chen M, E M, Zhang L, et al. Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study. J Natl Cancer Cent. 2023; 3(1): 65–71.